By administering intra-peritoneal injections of 0.5 mg/kg anti-ADAM8 antibody twice a week after tumor cell implantation in the mammary fat pad, substantial reductions were observed in the primary tumor size and burden, as well as in the number and size of brain metastases. Here, ADAM8 is linked to neoplasm.